Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-and-extend Eylea for diabetic macular oedema
ACTRN12618000428268Phase 4Completed
- Sponsor
- Nitin Verma
- Start
- Feb 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Nitin Verma. Primary endpoints: Best corrected visual acuity at 2 years and Proportion of participants with visual acuity improvement of at least 10 or 15 letters at 2 years. Started Feb 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12618000428268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000428268.